Trials / Completed
CompletedNCT04211740
Phase II Clinical Trial of OCH-NCNP1
Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- National Center of Neurology and Psychiatry, Japan · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary progressive mltiple sclerosis (SPMS) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OCH-NCNP1 | OCH-NCNP1 3mg is supplied as granules and take orally once a week. |
| DRUG | Placebo | Placebo is supplied as granules and take orally once a week. |
Timeline
- Start date
- 2019-12-06
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
- First posted
- 2019-12-26
- Last updated
- 2023-11-09
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04211740. Inclusion in this directory is not an endorsement.